Nick Thomas's Biography

• Home
• |
• Register
• |
• Submissions
  • Submission Guidelines
• |
• Agenda
  • Keynote Speakers
  • Agenda Day 1
  • Agenda Day 2
  • Round Table Discussions
• |
• Exhibition
• |
• Venue
• |
• Media
• |
• Posters
  • Submission Guidelines
• |

Cardiotoxicity of Oncology Drugs: High Content Screening of Bioenergetic Modulation of Kinase Inhibitor Mitochondrial Toxicity in hESC Derived Cardiomyocytes

Tuesday, 18 February 2014 at 11:30

Add to Calendar ▼2014-02-18 11:30:002014-02-18 12:30:00Europe/LondonCardiotoxicity of Oncology Drugs: High Content Screening of Bioenergetic Modulation of Kinase Inhibitor Mitochondrial Toxicity in hESC Derived CardiomyocytesADME and Predictive Toxicology in Barcelona, SpainBarcelona, SpainSELECTBIOenquiries@selectbiosciences.com

Human stem cells provide the potential for more physiologically relevant and predictive cellular toxicity assays for surveillance of drug liabilities. We have used Cytiva™ hESC derived cardiomyocytes to profile the phenotypic effects of a large panel of anticancer drugs and to identify bioenergetic modulation of cardiotoxicity.